News Releases & Events

News Releases & Events 2019

• 01/03 Medifocus, Inc. Announces Global Market Expansion with Prolieve® Performed and Reimbursed by Insurance Carriers in Hong Kong

News Releases & Events 2018

• 12/27 Medifocus, Inc. Announces Recent Publication Highlighting Its Focal Therapy for Prostate and Breast Cancer Treatment Initiatives

• 12/10 Uptick Newswire Featured Radio Interview: CEO Dr. William Jow of Medifocus, Inc., talks in detail about the development of The Prolieve System, the advantage of it’s use versus other treatments, and plans to fight prostate and breast cancers.

• 12/03 MEDIFOCUS, INC. ANNOUNCES FDA PMA SUPPLEMENT APPROVAL FOR NEW LABELING BASED ON SUCCESSFUL COMPLETION OF FDA POST APPROVAL STUDY (PAS) FOR THE PROLIEVE® THERMODILATATION™ DEVICE

• 11/29 Medifocus, Inc. Submits For New Patent Titled “Thermodilatation and Thermocompression to Facilitate Targeted Cluster Tissue Ablation and Immune Response”

• 11/27 Medifocus, Inc. Announces 26% Increase in Revenue in Recent Quarter and Positive Cash Flow from Operation for the Six Months Ended Sept 30, 2018

• 10/31 Uptick Newswire Featured Radio Interview: GM John Mon and Dr. Katz of Medifocus, Inc., discuss in detail the APA 1000 Breast Cancer Treatment System and the FDA approved Prolieve Thermodilatation System.

• 06/05 Medifocus, Inc. Announces Successful Completion of FDA Post Approval Study (PAS) for the Prolieve® Thermodilatation™ System

• 01/09 Medifocus, Inc. Expands its Reach into the Israeli Market with Amos Gazit Ltd for Its Prolieve® Thermodilatation for BPH Therapy and Announces Significant Debt Conversion into Shares

News Releases & Events 2017

• 08/28 Medifocus, Inc. Announces Significant Improvement in Operating Results for the Fiscal Year Ended March 31, 2017 with Successful Expansion of Prolieve® Global Market & Launching of Prolieve® Prostatitis Study

• 03/16 Medifocus, Inc. Announces First Ever Quarterly Operating Profit and Significant Improvement in Operating Results for the Nine Months Ended December 31, 2016

News Releases & Events 2016

• 10/03 Medifocus Inc. Announces Appointment of New Chief Executive Officer

• 09/14 Medifocus Inc. Announces Election of Directors and Financial Results for the Quarter Ended June 30 2016

• 01/13 Medifocus, Inc. Signs Research & Development and Manufacturing Agreement for Its Patented Technology of Heat-Activated and Tumor Targeted Immunotherapy and Gene Therapy

• 01/11 Medifocus, Inc. Announces the Engagement of Tanaka Kapec Design Group, Inc. as Lead Designer of Next Generation of Prolieve® Thermodilatation System

News Releases & Events 2015

• 12/14 Medifocus, Inc. Announces Closing of First Tranche of Units Offering

• 12/07 Medifocus, Inc. Announces Financial Results for the Six Months Ending September 30, 2015

• 10/19 Medifocus, Inc. Announces Presenting Papers at Biotechnology and Information Technology’s 5th Annual Symposium in Beijing, October 20-22, 2015

• 10/15 Medifocus, Inc. Announces Exclusive Agreement With Major Academic Medical Center to License Technology to Develop Heat-Activated and Tumor-Targeted Immunotherapy and Gene Therapy

• 09/30 Medifocus, Inc. Announces Major Milestone of 100,000 Prolieve(R) Treatments

• 09/28 Medifocus, Inc. Announces Units Offering

• 06/16 Medifocus, Inc. Appoints Christopher Kaplan to Its Strategic Advisory Board

• 06/04 Medifocus, Inc. Appoints Joseph M. Chalil to Its Strategic Advisory Board

• 05/27 Medifocus, Inc. Announces Option Agreement with Major Academic Medical Center to License Technology to Develop Heat Activated and Tumor Targeted Immunotherapy

• 05/12 Medifocus, Inc. Announces Closes Equity Offering

• 03/27 Medifocus, Inc. Announces Equity Offering

• 03/24 Medifocus, Inc. Announces Financial Results for the Nine Months Ending December 31, 2014

News Releases & Events 2014

• 12/15 Medifocus, Inc. Obtains Two Newly Allowed Canadian Patents on the Prevention and Safety for the Treatment for Breast Cancer

• 12/5 Medifocus, Inc.’s Technology Featured in a Mediaplanet Sponsored Insert in “USA Today” on Breast Cancer

 

• 11/25 Medifocus Inc. Announces Medifocus, Inc. Launches Advertising and Marketing Campaign to Increase Shareholder Awareness of Its Breast Cancer Technology

• 11/19 Medifocus Inc. Announces Medifocus Inc.’s Form 20-F Registration Statement Becomes Effective Immediately

• 11/07 Medifocus Inc. Announces Medifocus to Be Broadcast on BNN and Fox Business News on November 8th and 9th, 2014

• 10/23 Medifocus Inc. Announces Its Sponsorship at the VM Medical 20th Anniversary Breast Cancer Conference October 23rd

• 09/15 Medifocus Inc. Announces Closing of Private Placement September 15, 2014

• 07/30 Announces Financial Results for the Fiscal Year and Fiscal Fourth Quarter Ending March 31, 2014

• 07/09 Announces Medifocus, Inc. Is Issued New U.S. Patent for Thermoactivated Drugs and Gene Products

• 07/08 Announces Medifocus, Inc. Featured in Article in BioTuesdays

• 05/27 Medifocus, Inc. to Present at the SeeThruEquity 3rd Annual Microcap Investor Conference and the Third Annual Marcum MicroCap Conference

• 04/04 Medifocus, Inc. to Be Featured on BNN & Fox Business News Network on April 6, 2014

• 03/17 Expands its Reach into the Asia Pacific Market with the Engagement of Euro Japan Marketing Ltd. and Maxim Group, LLC

• 03/12 Announces Clinical Presentation at 24th Annual Interdisciplinary Breast Center Conference

• 03/11 Announces $2 Million Second Tranche Closing of $6 Million Convertible Debenture Financing

• 03/06 Announces Financial Results for the Third Fiscal Quarter and Nine Months Ending December 31, 2013

• 03/06 Obtains Newly Allowed European Patent Office EPO Patent

News Releases & Events 2013

• 12/18 Announces Closing of First Tranche of Debenture Financing

• 12/11 Announces VM Medical Center in Montreal Has Successfully Treated Its First Patient

• 12/4 Announces Record 294% Increase in Q2/FY 2014 Revenue

• 11/12 Announces Joint Venture with Ideal Concept Group, Ltd

• 08/29 Announces Revenue and Results of Operations for Fiscal First Quarter 2014

• 08/09 Announces the Initiation of Its Principal Investigational Site in Canada

• 07/31 New US Patent Covering the Use of Heat

• 07/29 Medifocus Inc. Announces Revenues for Year Ended March 31, 2013

• 07/24 Announces Maxim Group as Financial Advisor and Investment Banker

• 07/09 Announces DTC Eligibility of Stock

• 04/24 Announces Extension of Warrants

• 03/18 Announces Completion of Shares

• 02/25 New US Patent

• 02/14 Awarded Position on TSX

• 02/06 Launch of New Website

• 01/23 Acceleration of Prolieve Rollout

• 01/14 Closing of Private Placement

News Releases & Events 2012

• 12/17 Stock & Share Announcement

• 12/11 Increase in Size of Units Offering

• 12/06 Election & Reports First Revenue

• 11/30 Announces Units Offering

• 11/13 Extension of Warrants

• 11/1 Princeton Research: Money Info Show, November 1, 2012, Interview with Grant Walsh, Chairman of Medifocus, Inc.

• 10/22 Medifocus Inc. to Attend the 23rd Video Urology World Congress in Hong Kong on November 9-11: Sees Tremendous Opportunity in Asia for the Marketing of Prolieve(R)

• 10/15 Medifocus Inc. Chairman Grant Walsh Interviewed on the Stock Legends Radio Show

• 10/10 Cohen Independent Research Initiates Coverage on Medifocus Inc. With a Strong Buy Recommendation

• 10/10 Cohen Independent Research Report on Medifocus, Inc.

• 10/9 Medifocus Inc. Retains Consulting for Strategic Growth to Implement a Strategic Investor Relations & Public Relations Program

• 10/4 Medifocus Inc. to Attend Two Upcoming Regional American Urological Association (AUA) Meetings to Promote the Prolieve(R) Device System

• 09/27 Update on the Prolieve(R) Acquisition and the Hiring of the Prolieve(R) Management Team

• 09/24 S&P Capital IQ Initiates Coverage on Medifocus, Inc. in Standard & Poor’s Factual Stock Reports

• 07/25 Medifocus Inc. Completes Purchase of Prolieve(R) for the Treatment of Benign Prostatic Hyperplasia (BPH)

• 06/26 Acquisition of Prolieve(R) Device for Treatment of Benign Prostatic Hyperplasia from Boston Scientific

• 06/21 Closing of Private Placement Medifocus Inc.